{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:17:34Z","timestamp":1756383454826,"version":"3.44.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,28]]},"DOI":"10.7759\/cureus.91171","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:28:27Z","timestamp":1756380507000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy-Related Pneumonitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Nevra","family":"Gullu Arslan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sengul","family":"Aksakal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/107327480000700512","article-title":"Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Gu\u00e9rin treatments for bladder cancer","volume":"7","author":"Elkabani M","year":"2000","unstructured":"Elkabani M, Greene JN, Vincent AL, VanHook S, Sandin RL. Disseminated Mycobacterium bovis after intravesicular bacillus Calmette-Gu\u00e9rin treatments for bladder cancer. Cancer Control. 2000, 7:476-81. 10.1177\/107327480000700512","journal-title":"Cancer Control"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials","volume":"67","author":"Han RF","year":"2006","unstructured":"Han RF, Pan JG. Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006, 67:1216-23. 10.1016\/j.urology.2005.12.014","journal-title":"Urology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00720.x","article-title":"Bacille Calmette-Gu\u00e9rin in superficial transitional cell carcinoma","volume":"82","author":"Mungan NA","year":"1998","unstructured":"Mungan NA, Witjes JA. Bacille Calmette-Gu\u00e9rin in superficial transitional cell carcinoma. Br J Urol. 1998, 82:213-23. 10.1046\/j.1464-410x.1998.00720.x","journal-title":"Br J Urol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman BA","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X, et al.. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007, 109:1499-505. 10.1002\/cncr.22588","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi M","year":"2014","unstructured":"Brausi M, Oddens J, Sylvester R, et al.. Side effects of bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014, 65:69-76. 10.1016\/j.eururo.2013.07.021","journal-title":"Eur Urol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.05.006","article-title":"A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer","volume":"72","author":"Bilsen MP","year":"2018","unstructured":"Bilsen MP, van Meijgaarden KE, de Jong HK, et al.. A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer. Int J Infect Dis. 2018, 72:63-8. 10.1016\/j.ijid.2018.05.006","journal-title":"Int J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)37316-0","article-title":"Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer","volume":"147","author":"Lamm DL","year":"1992","unstructured":"Lamm DL, van der Meijden PM, Morales A, et al.. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992, 147:596-600. 10.1016\/s0022-5347(17)37316-0","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019180014","article-title":"Complications of intravesical BCG immunotherapy for bladder cancer","volume":"39","author":"Green DB","year":"2019","unstructured":"Green DB, Kawashima A, Menias CO, et al.. Complications of intravesical BCG immunotherapy for bladder cancer. Radiographics. 2019, 39:80-94. 10.1148\/rg.2019180014","journal-title":"Radiographics"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1086\/344908","article-title":"Spectrum of bacille Calmette-Gu\u00e9rin (BCG) infection after intravesical BCG immunotherapy","volume":"36","author":"Gonzalez OY","year":"2003","unstructured":"Gonzalez OY, Musher DM, Brar I, et al.. Spectrum of bacille Calmette-Gu\u00e9rin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis. 2003, 36:140-8. 10.1086\/344908","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11655-010-0787-y","article-title":"The regulatory effects of polyporus polysaccharide on the nuclear factor kappa B signal pathway of bladder cancer cells stimulated by bacillus Calmette-Guerin","volume":"17","author":"Wei JA","year":"2011","unstructured":"Wei JA, Zeng X, Han L, Huang Y. The regulatory effects of polyporus polysaccharide on the nuclear factor kappa B signal pathway of bladder cancer cells stimulated by bacillus Calmette-Guerin. Chin J Integr Med. 2011, 17:531-6. 10.1007\/s11655-010-0787-y","journal-title":"Chin J Integr Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00212-24","article-title":"BCG therapy in bladder cancer and its tumor microenvironment interactions","volume":"38","author":"Jian N","year":"2025","unstructured":"Jian N, Yu L, Ma L, Zheng B, Huang W. BCG therapy in bladder cancer and its tumor microenvironment interactions. Clin Microbiol Rev. 2025, 38:e0021224. 10.1128\/cmr.00212-24","journal-title":"Clin Microbiol Rev"},{"key":"ref12","article-title":"Pulmonary complications of intravesical bacille Calmette-Gu\u00e9rin immunotherapy","volume":"135","author":"Israel-Biet D","year":"1987","unstructured":"Israel-Biet D, Venet A, Sandron D, Ziza JM, Chretien J. Pulmonary complications of intravesical bacille Calmette-Gu\u00e9rin immunotherapy. Am Rev Respir Dis. 1987, 135:763-5.","journal-title":"Am Rev Respir Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Kamat AM","year":"2016","unstructured":"Kamat AM, Briggman J, Urbauer DL, et al.. Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to bacillus Calmette-Gu\u00e9rin. Eur Urol. 2016, 69:197-200. 10.1016\/j.eururo.2015.06.023","journal-title":"Eur Urol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1945-z","article-title":"Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer","volume":"66","author":"Pichler R","year":"2017","unstructured":"Pichler R, Gruenbacher G, Culig Z, et al.. Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer. Cancer Immunol Immunother. 2017, 66:427-40. 10.1007\/s00262-016-1945-z","journal-title":"Cancer Immunol Immunother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/386600-intravesical-bacillus-calmette-gurin-bcg-immunotherapy-related-pneumonitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:28:28Z","timestamp":1756380508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/386600-intravesical-bacillus-calmette-gurin-bcg-immunotherapy-related-pneumonitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.91171","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}